|
|||||
|
|

Global insurance underwriter SiriusPoint (NYSE:SPNT) posted $748.2 million of revenue in Q2 CY2025, up 17.5% year on year.
Is now the time to buy SPNT? Find out in our full research report (it’s free).
SiriusPoint’s second quarter results were met with a negative market reaction, as shares fell following the release. Management attributed the quarter’s performance to continued underwriting discipline, with CEO Scott Egan highlighting a core combined ratio improvement and strong premium growth in Accident & Health, Property, and select specialty lines. The company’s decision to increase net premium retention, particularly from managing general agent (MGA) partnerships, was cited as a driver of underlying return on equity. CFO Jim McKinney pointed to favorable prior-year reserve development and consistent service fee income from the company’s wholly owned Accident & Health MGAs, but also noted elevated losses in aviation and a deliberate reduction of exposure in the casualty segment as the company prioritized margin over volume.
Looking forward, SiriusPoint’s management framed their outlook around cautious capital allocation and a focus on lower volatility segments. Egan stated, “We want to take more net risk with partners who we feel more comfortable with,” signaling that growth will depend on the maturation and performance of existing MGA relationships. The company plans to continue expanding in Accident & Health and Property, while remaining prudent in areas like casualty and commercial auto. McKinney emphasized that expense discipline and selective risk-taking will be key, noting an expectation for expense ratios to remain within the 6.5% to 7% range, even as SiriusPoint pursues growth in international markets and new MGA partnerships.
Management attributed the quarter’s results to increased retention of profitable MGA business, strong Accident & Health growth, and disciplined exposure management across specialty segments. The team also highlighted international expansion and improved reserve development.
SiriusPoint’s guidance is shaped by selective risk-taking in high-confidence MGA partnerships, further Accident & Health growth, and disciplined expense management.
In the coming quarters, the StockStory team will be watching (1) whether SiriusPoint can maintain underwriting discipline and favorable reserve development as it expands MGA partnerships, (2) the persistence of growth in Accident & Health and Property amid changing market conditions, and (3) how effectively the company manages expense ratios while selectively increasing net risk. Developments in international expansion and shifts in reinsurance pricing will also be important signposts for future performance.
SiriusPoint currently trades at $19.25, down from $19.56 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).
When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.
Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
| 4 hours | |
| Oct-21 | |
| Oct-16 | |
| Oct-07 | |
| Oct-06 | |
| Oct-02 | |
| Sep-29 | |
| Sep-29 | |
| Sep-03 | |
| Sep-02 | |
| Aug-13 | |
| Aug-13 | |
| Aug-06 | |
| Aug-05 | |
| Aug-04 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite